Anaplastic Ependymoma
15
2
3
5
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
33.3%
5 terminated out of 15 trials
50.0%
-36.5% vs benchmark
7%
1 trials in Phase 3/4
120%
6 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (15)
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
Carboplatin and Bevacizumab for Recurrent Ependymoma
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors